| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $75.4M | — | +19.6% |
| SG&A Expense | $28.2M | — | +137.2% |
| Operating Income | -$103.6M | — | -38.3% |
| Net Income | -$97.4M | — | -35.2% |
| EPS (Basic) | -$0.53 | — | -1.9% |
| EPS (Diluted) | -$0.53 | — | -1.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $241.2M | -22.7% | +91.4% |
| Current Assets | $877.8M | -3.6% | +247.1% |
| Total Assets | $903.0M | -3.7% | +218.2% |
| Current Liabilities | $58.0M | -9.3% | +17.6% |
| Long-term Debt | $223.2M | +0.1% | — |
| Total Liabilities | $295.3M | -2.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$86.9M | — | -30.6% |
| Capital Expenditures | $449K | — | -17.9% |
| Investing Cash Flow | -$36.5M | — | -152.5% |
| Financing Cash Flow | $52.5M | — | +110.4% |
| Free Cash Flow | -$87.3M | — | -30.2% |
| +355.7% |
| Stockholders' Equity | $607.7M | -4.5% | +177.5% |